Free Trial

Korro Bio Q1 2023 Earnings Report

Korro Bio logo
$13.94 -0.81 (-5.46%)
As of 10:07 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Korro Bio EPS Results

Actual EPS
-$27.50
Consensus EPS
-$19.50
Beat/Miss
Missed by -$8.00
One Year Ago EPS
N/A

Korro Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Korro Bio Announcement Details

Quarter
Q1 2023
Time
N/A
Remove Ads

Korro Bio Earnings Headlines

Korro Bio appoints Loic Vincent as Chief Scientific Officer
EU’s Action Takes Aim At US Retirees
Trump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and global powers like China, Russia, and even Europe rapidly moving away from the U.S. dollar, central banks and financial giants are frantically buying gold at historic rates. This massive shift threatens your retirement savings with inflation and market instability—potentially worse than 2008. But you can protect yourself today by leveraging a little-known IRS loophole that lets you diversify your IRA or 401(k) into gold—tax-free and penalty-free.
Korro Bio: Promising Early Stage RNA Editing Company
See More Korro Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Korro Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Korro Bio and other key companies, straight to your email.

About Korro Bio

Korro Bio (NASDAQ:KRRO), a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

View Korro Bio Profile

More Earnings Resources from MarketBeat